Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2

Cancer-related anemia is present in more than 60% of newly diagnosed cancer patients and is associated with substantial morbidity and high medical costs. Drugs that enhance erythropoiesis are urgently required to decrease transfusion rates and improve quality of life. Clinical studies have observed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Dutta, Ritika, Zhang, Tian Yi, Köhnke, Thomas, Thomas, Daniel, Linde, Miles, Gars, Eric, Stafford, Melissa, Kaur, Satinder, Nakauchi, Yusuke, Yin, Raymond, Azizi, Armon, Narla, Anupama, Majeti, Ravindra
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Concise Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7108889/
https://ncbi.nlm.nih.gov/pubmed/31895700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI133344
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars